CytomX Therapeutics (NASDAQ:CTMX) Receives “Buy” Rating from Guggenheim

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “buy” rating restated by investment analysts at Guggenheim in a report issued on Monday,Benzinga reports. They currently have a $10.00 price objective on the biotechnology company’s stock. Guggenheim’s target price suggests a potential upside of 112.77% from the company’s current price.

Other analysts have also issued reports about the stock. Cantor Fitzgerald boosted their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, February 4th. Piper Sandler increased their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. HC Wainwright lifted their price target on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Barclays upped their price objective on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

CytomX Therapeutics Trading Up 0.4%

CTMX stock traded up $0.02 during trading on Monday, reaching $4.70. The stock had a trading volume of 174,555 shares, compared to its average volume of 3,100,192. The firm has a market cap of $796.32 million, a PE ratio of 11.75 and a beta of 2.44. The stock’s 50 day moving average is $5.12 and its two-hundred day moving average is $3.94. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $6.35.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds have recently modified their holdings of the company. Orbimed Advisors LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $19,208,000. Commodore Capital LP bought a new stake in CytomX Therapeutics during the second quarter valued at about $17,462,000. Perceptive Advisors LLC purchased a new position in shares of CytomX Therapeutics in the second quarter valued at about $15,876,000. Franklin Resources Inc. bought a new position in shares of CytomX Therapeutics in the second quarter worth about $13,096,000. Finally, Vivo Capital LLC bought a new position in CytomX Therapeutics in the 2nd quarter worth approximately $13,096,000. 67.77% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.